Compare TSSI & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSSI | PALI |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.6M | 240.2M |
| IPO Year | N/A | N/A |
| Metric | TSSI | PALI |
|---|---|---|
| Price | $7.79 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 1.1M | ★ 4.6M |
| Earning Date | 03-26-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.63 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $234,837,000.00 | N/A |
| Revenue This Year | $54.04 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $43.18 | ★ N/A |
| Revenue Growth | ★ 91.66 | N/A |
| 52 Week Low | $5.63 | $0.53 |
| 52 Week High | $31.94 | $2.64 |
| Indicator | TSSI | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 38.59 | 45.81 |
| Support Level | $7.86 | $1.65 |
| Resistance Level | $9.33 | $1.84 |
| Average True Range (ATR) | 0.82 | 0.13 |
| MACD | -0.25 | 0.02 |
| Stochastic Oscillator | 3.38 | 57.69 |
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.